New directions in multiple sclerosis therapy: matching therapy with pathogenesis.
All currently approved therapies for multiple sclerosis (MS) modulate systemic immune components prior to their entry into the central nervous system (CNS). Available data indicate they lack impact on the progressive phases of disease; the more potent systemic immune-directed agents predispose to development of infectious or neoplastic disorders. Development of new agents that enhance disease stage related efficacy and limit systemic toxicity will need to consider the underlying mechanisms related to each phase of the clinical disorder, namely relapses, remission, and progression. This report focuses on disease related mechanisms ongoing within the CNS that contribute to the different phases of MS and how these may serve as potential therapeutic targets. Such mechanisms include CNS compartment specific immunologic properties especially as related to the innate immune system and neural cell-related properties that are determinants of the extent of actual tissue injury and repair (or lack thereof).
Neuroimmunnology Unit, Montreal Neurologic Institute, Montreal, Quebec, Canada.
Jack
J
Antel
D000818:Animals; D002490:Central Nervous System / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology*; D009103:Multiple Sclerosis / Q000209:etiology / Q000276:immunology* / Q000628:therapy*; D014945:Wound Healing / Q000502:physiology*